Skip to main content
Eligibility
for people ages 18 years to 75 years
Location
at San Francisco, California and other locations
Dates
study started
estimated completion:
Principal Investigator

Description

Summary

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of ABT-494.

Official Title

A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease

Keywords

Crohn's Disease (CD) Crohn's Disease Tolerability ABT-494 Efficacy Safety

Eligibility

You can join if…

Open to people ages 18 years to 75 years

  • Participant must have completed Study M13-740 through Week 52.
  • If female, participant must be postmenopausal, surgically sterile or on using a birth control method.

You CAN'T join if...

  • For any reason participant is considered by the investigator to be an unsuitable candidate
  • Female participant with a positive pregnancy test at Baseline or who is considering becoming pregnant during the study.
  • Participant is not in compliance with prior and concomitant medication requirements and procedures throughout Study M13-740.

Locations

  • UCSD Health System (Pharma Only) /ID# 150041
    La Jolla, California, 92093, USA

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT02782663
Phase
Phase 2
Lead Scientist
Jonathan Terdiman
Study Type
Interventional
Last Updated
April 2017